EXHIBIT 10.1 AMENDED RESEARCH AND LICENCE AGREEMENT --------------------------------------Research and Licensing Agreement • November 5th, 2003 • Tissera Inc • Telegraph & other message communications
Case Study 4. Ball Horticulture and the South African National Biodiversity InstituteResearch and Licensing Agreement • December 22nd, 2020
In 1999 the then National Botanical Institute – NBI (now constituted as the South African National Biodiversity Institute - SANBI) entered into a Research and Licensing Agreement with the Chicago-based company Ball Horticulture. The five-year agreement (which continues to be renewed on a year to year basis), is the first North-South bioprospecting agreement in the horti- and flori-culture sector, and involves SANBI using its expertise to select South African plants of horticultural interest for Ball, both from its living collections and from the wild. SANBI is a public institution that aims to promote the sustainable use, conservation, appreciation and enjoyment of the exceptionally rich biodiversity of South Africa for the benefit of all people, and also to promote the economic use and potential of indigenous plants1. This it does through, inter alia, managing the various botanical gardens and herbaria in South Africa, conducting environmental education and outreach programmes, develo
CONFIDENTIAL TREATMENT REQUESTED RESEARCH AND LICENSING AGREEMENT betweenResearch and Licensing Agreement • December 18th, 2014 • Marika Inc. • Services-business services, nec
The Parties are jointly conducting research aimed at gaining fundamental insights in the realm of anticalins and lipocalins. To that effect the Parties signed a Research and Licensing Agreement on 26 June / 04 July 2003[***].
Amendment to Research and Licensing AgreementResearch and Licensing Agreement • December 28th, 2007 • Gammacan International Inc • Biological products, (no disgnostic substances) • New York
This Amendment to the Research and Licensing Agreement (the “Amendment”) is effective as of December 23rd,_, 2007 (“Effective Date"), by and among GammaCan Ltd. (“GammaCan”) and Tel Ha’Shomer-Medical Research Infrastructure and Services LTD. (“THM”). Each of THM and GammaCan shall be referred to as a "Party” or together as the "Parties”.
Research and licensing agreement for treatment of dyslipidemiaResearch and Licensing Agreement • July 5th, 2024
Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals for the development of products to treat dyslipidemia, including hypertriglyceridemia.
CONFIDENTIAL TREATMENT REQUESTResearch and Licensing Agreement • February 14th, 2008 • Gammacan International Inc • Biological products, (no disgnostic substances) • New York
[ * ] Indicates information that has been omitted pursuant to a confidential treatment request and this information has been filed under separate cover with the Commission.
CONFIDENTIAL TREATMENT REQUESTED RESEARCH AND LICENSING AGREEMENT betweenResearch and Licensing Agreement • March 30th, 2015 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
The Parties are jointly conducting research aimed at gaining fundamental insights in the realm of anticalins and lipocalins. To that effect the Parties signed a Research and Licensing Agreement on 26 June / 04 July 2003[***].
